Value Adjusted for Debt and Cash: Cerus Corporation (CERS)

Brandmark of Cerus Inc (CERS)

Cerus Corporation (CERS) possesses significant pricing power due to the patent protection of its technologies, which allows it to effectively offset inflation. The unique INTERCEPT system, which eliminates viruses in blood, ensures stable demand for consumables. The share price history on GURU.Markets with the 512.95 metric visualizes the dynamics of a business that dominates the pathogen reduction segment, serving the hospital sector worldwide.

Total Company Value: Cerus Corp (CERS) for 11/23/2025 - 10/30/2026

Cerus Corporation (CERS) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price Cerus Corp.|CERS - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Cerus|CERS - Total Company Value
- book capitalization information:
Net Assets per Share Cerus|CERS - Company Book Value|Market Cap to Net Assets Ratio cerus.com|CERS - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Cerus Corporation|CERS - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio cerus.com|CERS - Company Aggregate Debts|Debts to Net Assets Cerus|CERS - Company Long-Term Debts|Company Current Liabilities Cerus|Quick Ratio cerus.com
- company profitability and valuation multiples indicators:
CERS - Company Net Income
Summary company analytics:CERS Cerus Corp.
Manufactured product of Cerus Corp.

For an investor in Cerus Corporation (CERS), this metric serves as a measure of the business's real value, accounting for the potential of the INTERCEPT system within the transfusion safety sector. When analyzing the company's aggregate valuation, one should sum the market capitalization with the net debt, which determines the actual acquisition price of the enterprise, accounting for all liabilities and liquid assets.

Who Cerus Corporation competes with

Intuitive Surgical, Inc. (ISRG) - Total Enterprise Value|DHR - Total Company Value|Value Adjusted for Debt and Cash BDX (Becton Dickinson & Company)|STERIS plc (STE) - Total Company Value|WST - Company Buyout Price|Total Company Value Baxter|Real Price to Acquire Entire Company Masimo Corp (MASI)|Enterprise Value STVN|TFX - Total Enterprise Value|Enterprise Value MMSI (Merit Medical Systems)|NVST: Business Value|ICU Medical - Enterprise Value|Company Buyout Price Dentsply Sirona Inc XRAY|LMAT: Enterprise Value|Real Price to Acquire Entire Company AtriCure Medical|STAA (STAAR Surgical Company) - Enterprise Value|Enterprise Value Niagen|Total Company Value ZimVie (ZIMV)|Total Company Value ANGO (AngioDynamics Inc)|Alpha Teknova Inc - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash MGRM|Sharps Tech - Enterprise Value|Company Buyout Price InfuSystem Holdings INFU|Utah Medical Products, Inc. (UTMD) - Total Company Value|Business Value KRMD|Total Company Value Nyxoah, S.A.|Microbot Medical, Inc (MBOT) - Company Buyout Price|Real Price to Acquire Entire Company PDEX (Pro-Dex, Inc.)|Aggregate Business Value ZTEK|Total Company Value Elutia ELUT|Value Adjusted for Debt and Cash MLSS|NXGL: Real Price to Acquire Entire Company|RVP - Enterprise Value|Harvard Bioscience (HBIO) - Total Company Value|Real Price to Acquire Entire Company femasys.com|MHUA (Meihua Medical Technologies) - Enterprise Value|Total Enterprise Value Predictive Oncology Corp POAI|Total Company Value Callan JMB Inc (CJMB)|Atrion Corporation Inc. - Business Value|NeuroMetrix, Inc. - Real Price to Acquire Entire Company